Voyager Acquisition
Yahoo Finance • last month
VERAXA Biotech Strengthens Financial Position with $27.5 Million Principal Amount Senior Secured Note Financing and $50 Million Share Purchase Agreement
Transactions Provide Financial Flexibility to Advance Pipeline of Next Generation Cancer Therapies Comprised of Novel Bispecific T-cell Engagers (TCEs) and Antibody-Drug Conjugates (ADCs)Support Closing of Business Combination with Voyager... Full story
Yahoo Finance • 8 months ago
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger–PBBK, VACH, LCTC, and SMLR
NEW YORK, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in th... Full story
- NOW
Mentioned:
Yahoo Finance • 9 months ago
VERAXA Biotech and Secarna Pharmaceuticals Initiate Antibody Oligonucleotide Conjugate Alliance in Immunology
ZURICH, SWITZERLAND, and MARTINSRIED/MUNICH, GERMANY – September 30, 2025 --VERAXA Biotech, an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ:VACH, “Voyager”... Full story
- T
Mentioned:
Yahoo Finance • 11 months ago
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Voyager Acquisition Corp. (NASDAQ: VACH)
NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the... Full story